Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
VY1706 Alzheimer's Gene Therapy Achieves 75% Tau Reduction in GLP Studies
VY1706 Alzheimer's Gene Therapy Achieves 75% Tau Reduction in GLP Studies
Read also
FDA Grants RMAT Designation to Lexeo Therapeutics for LX2020 Gene Therapy
Lexeo Therapeutics receives FDA RMAT designation for LX2020, an investigational AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy.
AMT-191 Gene Therapy Shows Major Clinical Benefits in Fabry Disease Trial
uniQure’s investigational gene therapy AMT-191 boosted alpha-Gal A enzyme levels, allowing all dosed Fabry disease patients to stop replacement therapy.
FDA Grants Fast Track Designation to Modzatinib for Lichen Planus Treatment
Aclaris Therapeutics receives FDA Fast Track Designation for modzatinib (ATI-2138) to treat moderate to severe lichen planus. Phase 2b trial expected soon.
UC Davis Clinical Trial Reveals Best Air Purifiers for Asthma & Allergies
UC Davis and CARB conducted the largest clinical trial to find the best air purifiers for asthma and allergy control, highlighting HyperHEPA technology.
